APO-T appoints Dr. Marta Kijanka as Vice-President of R&D.
APO-T opens new laboratory and office facilities at PivotPark in Oss, the Netherlands, and expands its R&D staff.
The Netherlands Enterprise Agency (RvO) grants APO-T an “Innovation Credit” for the development of its AIM therapy for the treatment of i.a. AML/MM. The credit consists of an investment of €1.5 million to support preclinical studies and a planned Phase I/II study.
Dutch biotech company APO-T announces the successful completion of a Series B equity financing round by existing shareholders participating. The proceeds will be used to accelerate the clinical development of APO-T's proprietary AIM technology and to expand the company’s capabilities in the area of formats such as ADC's.
APO-T expands its Executive Board with Dr. Erwin Houtzager as Chief Scientific Officer. Erwin Houtzager (1962; PhD Molecular Biology) is a seasoned professional in pre-clinical antibody development. He has been working from 1998 till 2001 at Ubisys at which he formed the basis for Crucell after a merger with Introgene. In 2001 Erwin founded Catchmabs.
APO-T B.V. and LinXis B.V. both privately held oncology companies, announced that LinXis has granted APO-T an exclusive worldwide license for the development and commercialization of fully-human antibody-drug-conjugates (ADC) using APO-T’s MAGE-HLA targeted antibodies and LinXis’ unique LX linker technology. In exchange, LinXis will receive certain milestone payments upon the achievement of e.g. clinical development and sales milestones, and royalties on worldwide net sales resulting from commercialized products.